AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02712957 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naproxen placebo
Description: inactive substance
Study NCT03174015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bauleni Secret
Description: The intervention will invite enrolled landlords to a series of meetings in which various mechanisms will be used, each designed to increase their likelihood of improving the toilet(s) on their plot. These meetings will be the main vehicle for a status-building campaign associated with increasing wealth by improving plot sanitation, understanding tenants' implicit demand, understanding the processes by which toilets can be improved, and a competition rewarding landlords that make the greatest improvements to the improvement of their toilet(s).
Study NCT01104883 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor-Canal-Blockade
Description: US-guided Adductor-Canal-Blockade with ropivacaine 7,5 mg/ml
Study NCT01104883 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Adductor-Canal-blockade with saline
Description: US-guided Adductor-Canal-blockade with saline
Study NCT01664676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Study NCT01664676 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-liraglutide
Study NCT05155748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous education and knowledge exchange
Description: The intervention is educational and directed at the complete nursing home care team.
Study NCT01754064 — intervention group
Intervention type: DEVICE
Intervention: Cardiac Rhythm Management device
Study NCT02573259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06801591
Description: IV every 21 days (Part 1)
Study NCT02573259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06801591
Description: 300 mg SC every 28 days (Part 1 and 2)
Study NCT00631254 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allergen challenge
Description: Conventional allergen challenge: increasing allergen doses given by nebulisation through the mouth and stopped when a 20% fall in forced expiratory volume in one second is obtained.~Low dose allergen challenge: very low allergen doses given by nebulisation through the mouth. No more than a 5% fall in forced expiratory volume in one second.~Nasal allergen challenge: One drop of increasing allergen doses on nasal mucosa.
Study NCT00631254 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allergen challenge
Description: Low dose allergen challenge: very low allergen doses given by nebulisation through the mouth. No more than a 5% fall in forced expiratory volume in one second.~Nasal allergen challenge: One drop of increasing allergen doses on nasal mucosa.
Study NCT03158168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candida Antigen
Description: Candida Albicans Antigen injection
Study NCT03158168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Sulfate
Description: Zinc Sulfate injection
Study NCT00190424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CpG-ODN
Study NCT04036721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolonged glucocorticosteroid (prednisone) regimen
Description: Prolongation of maintenance therapy with prednisone of patients with pneumonitis inducted by anyi-PD-1/anti-PD-L1 antibodies.
Study NCT04036721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Short glucocorticosteroid (prednisone) regimen
Description: Prednison regimen based upon American Society of Clinical Oncology and European Society for Medical Oncology Clinical Practice Guidelines on pneumonitis treatment in patients receiving immunotherapy agents
Study NCT01138020 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Intervention
Description: Cognitive rehabilitation treatment designed specifically to address the most common cognitive complaints in executive and memory function
Study NCT01138020 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational intervention
Description: Educational intervention is geared at personal management of TBI-related symptoms.
Study NCT03188055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Case/Worst Case communication tool
Description: The communication tool promotes dialogue and patient deliberation, and supports shared decision making in the context of life-limiting illness. Building on a conceptual model of shared decision-making proposed and the practice of scenario planning our intervention is designed to lead to a discussion of patient preferences and consideration of outcomes.~The surgeon verbally describes the best case, worst case, and most likely outcomes for each treatment option-incorporating rich narrative from clinical experience and translation of probabilistic information-while drawing a diagram of those options. The surgeon also writes details about each option on the diagram. The narrative and graphic help family and patients formulate and express preferences.
Study NCT03163407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Treatment of the postspinal anesthesia hypotension by administrating 5 mcg of Norepinephrine intravenously every 3 min until normal systolic blood pressure
Study NCT03163407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: Management of the post spinal hypotension by administrating 6 mg of Ephedrine intravenously every 3 min
Study NCT02154438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: ketamine 0.5mg/kg loading followed by 0.5mg/kg/h infusion during operation
Study NCT02316639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Training
Description: The established Neuromuscular Training (NMT) protocol is supervised, progressive program in which the patient maintains balance on three different support surfaces while a clinician administers purposeful manipulations of the support system.1 The patient maintains a single-leg stance on the rollerboard and tiltboard surfaces, and a two-leg stance with one foot on a roller board while the other is on a platform. Participants will complete two training sessions per week, for five weeks for a total of 10 training sessions.
Study NCT03030625 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: IGRT/VMAT focal therapy boost to DIL
Description: Image-guided/VMAT focal Intensification dose to intraprostatic dominant lesion in men with localized prostate cancer (PCa) of intermediate and high risk (criteria NCCN) eligible to receive radiotherapy
Study NCT00763789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: local anaesthesia and remifentanil sedation
Study NCT00763789 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: total intravenous anaesthesia
Study NCT01859182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib
Description: Given PO
Study NCT01859182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt inhibitor MK2206
Description: Given PO
Study NCT01859182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01859182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: Correlative studies
Study NCT01859182 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT00974363 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Sampling
Description: A blood sample will be taken yearly at each long-term follow-up visit (i.e. Year 2 through Year 5) after vaccination during the primary study. No vaccines are administered in the long-term follow-up study
Study NCT03312413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride
Description: Dexmedetomidine Hydrochloride 0.2 μg·kg-1·h-will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
Study NCT03312413 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline 0.5 mL·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
Study NCT03312413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride
Description: Dexmedetomidine Hydrochloride 0.5 μg·kg-1·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
Study NCT03312413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride
Description: Dexmedetomidine Hydrochloride 0.7 μg·kg-1·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
Study NCT03064399 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: without lateral ligament repairment
Description: microfracture without repairment of the lateral ligament
Study NCT03064399 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lateral ligament repairment
Description: microfracture combined with repairment of the lateral ligament
Study NCT02539459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg tablets
Study NCT00447564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probuphine
Description: 4 implants
Study NCT00447564 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 4 implants
Study NCT04295967 — intervention group
Intervention type: OTHER
Intervention: formalin fixed paraffin embedded blocks
Description: The study will be conducted using formalin fixed paraffin embedded blocks of seventy cases of urothelial carcinomas .CD31-PAS dual-staining will be performed to confirm the presence of VM.
Study NCT01640639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Thalidomide, pill, 50 mg, once p.d., 6 weeks
Study NCT01640639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, pill, once p.d., 6 weeks
Study NCT03957369 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HIV-1 plasma RNA Genotyping secuencing by Sanger technique
Description: After signing informed consent, we will collect whole blood for HIV genotyping in plasma HIV-1 RNA for testing of resistance-associated mutations to reverse transcriptase, protease, and integrase enzymes.
Study NCT03957369 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HIV-1 plasma RNA Genotyping secuencing by Ultra-deep sequencing technique
Description: After signing informed consent, we will collect whole blood for HIV genotyping in plasma HIV-1 RNA for testing of resistance-associated mutations to reverse transcriptase, protease, and integrase enzymes.
Study NCT01406470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™
Description: IVIG-SN™ 10g/200mL, dose is 300-900 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with IVIG-SN™ will be 12 months with a 3 month follow-up.
Study NCT01721928 — intervention group
Intervention type: DEVICE
Intervention: Continuous venovenous hemodialysis
Description: Continuous venovenous hemodialysis
Study NCT00680992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: 120 mg administered subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.
Study NCT00974363 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Sampling
Description: A blood sample will be taken yearly at each long-term follow-up visit (i.e. Year 2 through Year 5) after vaccination during the primary study. No vaccines are administered in the long-term follow-up study
Study NCT00808067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran dose 1
Description: dabigatran high dose twice daily
Study NCT00808067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran dose 2
Description: dabigatran low dose twice daily
Study NCT04321421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hyperimmune plasma
Description: administration of hyperimmune plasma at day 1 and based on clinical response on day 3 and 5
Study NCT02275429 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood test
Description: blood will be drawn the day before the race (day 0), upon completion of the race (between 27 and 67 hours after departure), and on days 7 and 28
Study NCT00513305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arsenic trioxide
Description: Arsenic trioxide will be administered intravenously (iv) at a dose of 0.25 mg/kg.
Study NCT00513305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose cytarabine alone
Description: Cytarabine will be administered at a dose of 10 mg/m\^2 subcutaneously (sc) twice a day (bid).
Study NCT02922504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music intervention group
Study NCT02922504 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Controlled group
Study NCT03049553 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cobas HPV-DNA test
Description: Cobas HPV-DNA testing device from Roche is already in standard use in the Danish screening program for purpose of triage and primary screening of women 60+. It has four signals; HPV-negative, HPV-16, HPV-18 and other
Study NCT04502017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA plus Clopidogrel
Description: OAC (6 weeks) + DAPT (until 6 months) + ASA
Study NCT04502017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genetic-Tailored AntiThrombotic Strategy
Description: Half-Dose OAC or Clopidogrel in combination with ASA on the basis of CYP2C19 Genotype
Study NCT04502017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Half-Dose of novel OAC
Description: Half Dose of novel OAC post-device Implantation
Study NCT04032184 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride toothpaste
Description: regimen using fluoride toothpaste
Study NCT04032184 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluoride toothpaste and chlorhexidine mouthwash
Description: regimen using fluoride toothpaste and chlorhexidine mouthwash
Study NCT04032184 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluoride toothpaste, chlorhexidine mouthwash, MI varnish
Description: regimen using fluoride toothpaste, chlorhexidine mouthwash, MI varnish
Study NCT00515723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: randomized to 12 week trial of risperidone.
Study NCT00515723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: randomized to 12 week trial of olanzapine.
Study NCT00515723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quetiapine
Description: randomized to 12 week trial of quetiapine.
Study NCT00515723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ziprasidone
Description: randomized to 12 week trial of ziprasidone.
Study NCT02461953 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hemoperfusion apparatus
Study NCT02461953 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low flux dialyzer
Study NCT02461953 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high flux dialyzer
Study NCT00701649 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYT006-AngQb
Description: s.c.
Study NCT00701649 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: s.c.
Study NCT02923791 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim Hospira
Description: 5 consecutive daily doses (Days 1-5) in Period 1 and 1 dose (Day 1) in Period 2.
Study NCT02923791 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US-Approved Neupogen
Description: 5 consecutive daily doses (Days 1-5) in Period 1 and 1 dose (Day 1) in Period 2.
Study NCT00552929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: After induction of anesthesia an intubation dose of a neuromuscular blocking agent (NMBA) was administered IV: either 0.9 mg/kg rocuronium (arms 1-5) or 0.1 mg/kg vecuronium (arms 6-10). Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of sugammadex (0.5 to 8.0 mg/kg) IV was administered.
Study NCT01789047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Description: Topiramate as adjunct to amantadine
Study NCT01789047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control
Study NCT01789047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amantadine
Description: Existing treatment for all participants
Study NCT04199845 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PS128
Description: PS128 or placebo will be given twice daily for 8 weeks.
Study NCT01789047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amantadine
Description: Existing treatment for all participants
Study NCT04213664 — intervention group
Intervention type: OTHER
Intervention: prognosis
Description: cancer and overall survival cancer specific survival cancer and recurrence-free survival cancer and disease-free survival lymphocyte to monocyte ratio in non-metastatic renal cancer and progression-free survival
Study NCT04199845 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PS128
Description: PS128 or placebo will be given twice daily for 8 weeks.
Study NCT01187381 — intervention group
Intervention type: DRUG
Intervention: Trastuzumab
Description: Trastuzumab according to local standard of care and in line with the current summary of product characteristics/ local guidelines
Study NCT04367285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensor-based Training
Description: Sensor-based Training consists of twelve sessions of upper limb training with PABLO®-Tyromotion. For each session the training consists in interactive-games based on virtual reality which allowed a task-oriented approach and a neurocognitive feedback. The exercises require precision tasks and one-dimensional and bidimensional reaction, allowing to train the attention, the strength control and movement control, the coordination and the movement precision. The interactive-games were chosen from those proposed by the Tyromotion PABLO® System.
Study NCT04367285 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Upper limb motor training
Description: Upper limb motor training, without robotic support. Subjects performed specific exercises aimed to recovery global upper limb functions, to control hand grasp and to improve hand's fine movements.
Study NCT00576563 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: FDG
Description: contrast medium
Study NCT03762200 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SURGICEL Powder
Description: SURGICEL Powder is a topical absorbable hemostatic treatment made of oxidized regenerated cellulose (ORC) - plant material
Study NCT02153151 — intervention group
Intervention type: OTHER
Intervention: Cytology specimen
Description: Correlative studies
Study NCT02153151 — intervention group
Intervention type: OTHER
Intervention: Laboratory biomarker analysis
Description: Correlative studies
Study NCT01728337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dysport
Description: Dysport® was injected on the right side of the forehead and Xeomin® was injected on the left side of the forehead.
Study NCT01728337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xeomin
Description: Xeomin® was injected on the right side of the forehead and Dysport® was injected on the left side of the forehead
Study NCT00384397 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Description: 0.5 mL, Intramuscular
Study NCT00384397 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Description: 0.5 mL, Intramuscular
Study NCT04558892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Study NCT04558892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Study NCT02078271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FBDG group
Description: The group received food based dietary guidelines for complementary feeding
Study NCT02078271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stimulation
Description: The group received psychosocial stimulation
Study NCT02078271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combinded FBDG and stimulation
Description: The group received both FBDG and psychosocial stimulation
Study NCT02078271 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Study NCT02102048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir
Study NCT01681758 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IV fluid according to PPV
Description: intravenous fluids
Study NCT01681758 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: fluids according to standard care